Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

WALGREENS BOOTS ALLIANCE, INC.

(WBA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Walgreens Boots Alliance : Company deploying proceeds of $6.5 billion to pay down debt and boost strategic healthcare investments Extended and expanded commercial agreements to drive incremental growth and synergies (Form 8-K)

06/04/2021 | 05:13pm EDT

Company deploying proceeds of $6.5 billion to pay down debt and boost strategic healthcare investments

Extended and expanded commercial agreements to drive incremental growth and synergies

DEERFIELD, Ill., June 2, 2021 - Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced it has completed the sale of its Alliance Healthcare businesses to AmerisourceBergen for total consideration of approximately $6.5 billion, made up of $6.275 billion in cash (subject to a customary net cash and working capital adjustment) and 2 million shares of AmerisourceBergen common stock. The company will use the cash proceeds to reduce debt and accelerate growth of its core retail pharmacy and healthcare businesses.

The company has used a portion of the funds to repay the outstanding amount owed on a $3.8 billion term loan that funded the bond tender completed by the company on April 26, 2021. This has eliminated $3.3 billion in debt from the company's balance sheet. The remaining net cash proceeds are planned to be invested in strategic opportunities and to expand healthcare offerings to help accelerate the company's growth strategy.

These investments will further build on previously announced initiatives, including WBA's investment in VillageMD to support the opening of 600-700 Village Medical at Walgreens primary care clinics, as well as WBA's acquisition of a majority stake in iA, a leading-edge provider of software-enabled pharmacy automation solutions.

'Completion of this transaction represents a significant step forward in our transformation and will fuel investments to grow WBA's core retail pharmacy and healthcare businesses,' said Rosalind Brewer, CEO, Walgreens Boots Alliance. 'Through these and other investments, WBA looks to bring even more innovative healthcare offerings to our customers and patients, as we further accelerate our strategic priorities.'

WBA and AmerisourceBergen will also execute on the expansion and extension of commercial agreements that are expected to drive incremental growth and synergies.

About Walgreens Boots Alliance

Walgreens Boots Alliance (Nasdaq: WBA) is a global leader in retail pharmacy, impacting millions of lives every day through dispensing medicines, and providing accessible, high-quality care. With more than 170 years of trusted healthcare heritage and innovation in community pharmacy, the company is meeting customers' and patients' needs through its convenient retail locations, digital platforms and health and beauty products.

Including equity method investments, WBA has a presence in more than 25 countries, employs more than 450,000 people and has more than 21,000 stores.

WBA's purpose is to help people across the world lead healthier and happier lives. The company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. WBA is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business.

WBA is included in FORTUNE's 2021 list of the World's Most Admired Companies*. This is the 28th consecutive year that WBA or its predecessor company, Walgreen Co., has been named to the list.

More company information is available at www.walgreensbootsalliance.com.

*© 2021, Fortune Media IP Limited. Used under license.

(WBA-GEN)

Cautionary Note Regarding Forward-Looking Statements:

All statements in this release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements about the divestiture and related strategic transactions, the expected use of proceeds from the divestiture, the benefits and synergies of the divestiture and related strategic transactions, and future opportunities for WBA. They also include any other statements regarding WBA's future operations, financial or operating results, capital allocation, anticipated debt levels and ratios, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. Words such as 'expect,' 'likely,' 'outlook,' 'forecast,' 'preliminary,' 'pilot,' 'project,' 'intend,' 'plan,' 'goal,' 'target,' 'aim,' 'continue,' ' 'believe,' 'seek,' 'anticipate,' 'upcoming,' 'may,' 'possible,' and variations of such words and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, known or unknown, that could cause actual results to vary materially from those indicated or anticipated. These risks, assumptions and uncertainties include those described in Item 1A (Risk Factors) of our Annual Report on Form 10-K for the fiscal year ended August 31, 2020 and in other documents that we file or furnish with the Securities and Exchange Commission. If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. All forward-looking statements we make or that are made on our behalf are qualified by these cautionary statements. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made.

We do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

Media Relations

U.S. / Morry Smulevitz +1 847 315 0517

International +44 (0)20 7980 8585

Investor Relations

Gerald Gradwell and Jay Spitzer +1 847 315 2922

Source: Walgreens Boots Alliance

Disclaimer

Walgreens Boots Alliance Inc. published this content on 04 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 June 2021 21:12:04 UTC.


© Publicnow 2021
All news about WALGREENS BOOTS ALLIANCE, INC.
07/26WALGREENS BOOTS ALLIANCE : and VillageMD Expand to Northern Indiana, Opening New..
AQ
07/23WALGREENS BOOTS ALLIANCE : VillageMD to Open Village Medical Practices in Indian..
MT
07/23WALGREENS BOOTS ALLIANCE : and VillageMD Expand to Northern Indiana, Opening New..
BU
07/23Walgreens and VillageMD Expand to Northern Indiana, Opening New Full-Service ..
CI
07/21Drugmakers, pharmacies next targets for U.S. opioid settlements
RE
07/20New York, drug distributors reach $1.18 billion opioid settlement as national..
RE
07/20WALGREENS BOOTS ALLIANCE, INC. : Change in Directors or Principal Officers (form..
AQ
07/20Walgreens Boots Alliance, Inc. Announces Executive Changes
CI
07/20PLx Shares Rise as Walgreens Set to Carry Vazalore in Stores
DJ
07/19PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwid..
CI
More news
Financials (USD)
Sales 2021 132 B - -
Net income 2021 2 592 M - -
Net Debt 2021 9 638 M - -
P/E ratio 2021 16,0x
Yield 2021 3,99%
Capitalization 40 689 M 40 689 M -
EV / Sales 2021 0,38x
EV / Sales 2022 0,36x
Nbr of Employees 277 000
Free-Float 61,0%
Chart WALGREENS BOOTS ALLIANCE, INC.
Duration : Period :
Walgreens Boots Alliance, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WALGREENS BOOTS ALLIANCE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Last Close Price 47,04 $
Average target price 52,97 $
Spread / Average Target 12,6%
EPS Revisions
Managers and Directors
Rosalind Gates Brewer Chief Executive Officer & Director
James Kehoe Global Chief Financial Officer & Executive VP
Stefano Pessina Executive Chairman
Francesco Tinto Global Chief Information Officer & Senior VP
Ornella Barra Chief Operating Officer
Sector and Competitors